{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:37Z","timestamp":1793325757556,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nontuberculous mycobacteria (NTM) are ubiquitous, environmental bacteria that can cause chronic lung disease. Persons with cystic fibrosis (pwCF) are at high risk for NTM. Approximately 1 in 5 pwCF in the United States (U.S.) is affected by pathogenic NTM species, and incidence rates of NTM have been increasing among pwCF as well as in the general population. Prevalence of NTM pulmonary infections (PI) varies widely across the United States because of geographic variation in environmental exposures. This study will present updated region-level incidence of NTM infections in the cystic fibrosis (CF) population in the U.S.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used the Cystic Fibrosis Foundation Patient Registry (CFFPR) data for the period 2010 through 2019. Our study population comprised persons with CF\u2009\n                      <jats:underline>\u2265<\/jats:underline>\n                      \u200912 years of age who had been tested for NTM PI. We included only registry participants with NTM culture results. We defined incident cases as persons with one positive mycobacterial culture preceded by\n                      <jats:underline>\u2265<\/jats:underline>\n                      \u2009two negative mycobacterial cultures. We defined non-cases as persons with\n                      <jats:underline>\u2265<\/jats:underline>\n                      \u2009two negative mycobacterial cultures. We estimated average annual NTM PI incidence by region. Using quasi-Poisson models, we calculated annual percent change in incidence by region.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 3,771 incident NTM infections. Of these cases, 1,816 (48.2%) were\n                      <jats:italic>Mycobacterium avium<\/jats:italic>\n                      complex (MAC) infections and 960 (25.5%) were\n                      <jats:italic>Mycobacterium abscessus<\/jats:italic>\n                      infections. The average annual incidence of NTM PI among pwCF in the U.S. was 58.0 cases per 1,000 persons. The Northeast had the highest incidence of MAC (33.5\/1,000 persons tested) and the South had the highest incidence of\n                      <jats:italic>M. abscessus<\/jats:italic>\n                      (20.3\/1,000 persons tested). From 2010 to 2019, the annual incidence of total NTM PI increased significantly by 3.5% per year in the U.S.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NTM PI incidence is increasing among pwCF. Identifying high risk areas and increasing trends is important for allocating public health and clinical resources as well as evaluating interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08468-6","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T06:02:17Z","timestamp":1690178537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010\u20132019)"],"prefix":"10.1186","volume":"23","author":[{"given":"Julia E.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Mercaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettie M.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Rebecca.","family":"Prevots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"issue":"9","key":"8468_CR1","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3201\/eid2609.200749","volume":"26","author":"SG Dean","year":"2020","unstructured":"Dean SG, Ricotta EE, Fintzi J, Lai YL, Kadri SS, Olivier KN, et al. Mycobacterial testing Trends, United States, 2009\u20132015(1). Emerg Infect Dis. 2020;26(9):2243\u20136.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"8468_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","volume":"17","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of Nontuberculous Mycobacterial Lung Disease in a large U.S. Managed Care Health Plan, 2008\u20132015. Ann Am Thorac Soc. 2020;17(2):178\u201385.","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"8468_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","volume":"15","author":"J Adjemian","year":"2018","unstructured":"Adjemian J, Olivier KN, Prevots DR. Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum positivity in patients with cystic fibrosis in the United States, 2010\u20132014. Annals of the American Thoracic Society. 2018;15(7):817\u201326.","journal-title":"Annals of the American Thoracic Society"},{"issue":"2","key":"8468_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","volume":"9","author":"CR Esther Jr","year":"2010","unstructured":"Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros. 2010;9(2):117\u201323.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"8468_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1164\/rccm.200207-679OC","volume":"167","author":"KN Olivier","year":"2003","unstructured":"Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003;167(6):835\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"8468_CR6","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","volume":"71","author":"RA Floto","year":"2016","unstructured":"Floto RA, Kenneth NO, Lisa S, Charles LD, Jean-Louis H, Jerry AN, et al. US cystic Fibrosis Foundation and european cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71(Suppl 1):i1.","journal-title":"Thorax"},{"issue":"7","key":"8468_CR7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","volume":"13","author":"EA Knapp","year":"2016","unstructured":"Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, et al. The cystic Fibrosis Foundation Patient Registry. Design and methods of a National Observational Disease Registry. Ann Am Thorac Soc. 2016;13(7):1173\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"8468_CR8","unstructured":"United States. ZIP Code Database."},{"key":"8468_CR9","volume-title":"R: a language and environment for statistical computing","author":"RC Team","year":"2021","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"issue":"1","key":"8468_CR10","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","volume":"56","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535.","journal-title":"Eur Respir J"},{"key":"8468_CR11","doi-asserted-by":"crossref","unstructured":"Ricotta EE, Prevots DR, Olivier KN. CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011\u20132018. ERJ Open Res. 2022;8(2).","DOI":"10.1183\/23120541.00724-2021"},{"issue":"4","key":"8468_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccm.2022.06.010","volume":"43","author":"SL Martiniano","year":"2022","unstructured":"Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med. 2022;43(4):697\u2013716.","journal-title":"Clin Chest Med"},{"issue":"11","key":"8468_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1513\/AnnalsATS.201611-860OC","volume":"14","author":"AB Spaulding","year":"2017","unstructured":"Spaulding AB, Lai YL, Zelazny AM, Olivier KN, Kadri SS, Prevots DR, et al. Geographic distribution of Nontuberculous Mycobacterial Species identified among clinical isolates in the United States, 2009\u20132013. Ann Am Thorac Soc. 2017;14(11):1655\u201361.","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"8468_CR14","doi-asserted-by":"publisher","first-page":"e0259964","DOI":"10.1371\/journal.pone.0259964","volume":"16","author":"SL Foote","year":"2021","unstructured":"Foote SL, Lipner EM, Prevots DR, Ricotta EE. Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida. PLoS ONE. 2021;16(12):e0259964.","journal-title":"PLoS ONE"},{"issue":"2","key":"8468_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41370-021-00360-2","volume":"32","author":"EM Lipner","year":"2022","unstructured":"Lipner EM, Crooks JL, French J, Strong M, Nick JA, Prevots DR. Nontuberculous mycobacterial infection and environmental molybdenum in persons with cystic fibrosis: a case-control study in Colorado. J Expo Sci Environ Epidemiol. 2022;32(2):289\u201394.","journal-title":"J Expo Sci Environ Epidemiol"},{"issue":"4","key":"8468_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1513\/AnnalsATS.202101-053OC","volume":"19","author":"EM Lipner","year":"2022","unstructured":"Lipner EM, French JP, FalkinhamIII JO, Crooks JL, Mercaldo RA, Henkle E, et al. Nontuberculous mycobacteria infection risk and Trace Metals in Surface Water: a Population-based ecologic epidemiologic study in Oregon. Annals of the American Thoracic Society. 2022;19(4):543\u201350.","journal-title":"Annals of the American Thoracic Society"},{"key":"8468_CR17","doi-asserted-by":"publisher","first-page":"144552","DOI":"10.1016\/j.scitotenv.2020.144552","volume":"763","author":"S DeFlorio-Barker","year":"2021","unstructured":"DeFlorio-Barker S, Egorov A, Smith GS, Murphy MS, Stout JE, Ghio AJ, et al. Environmental risk factors associated with pulmonary isolation of nontuberculous mycobacteria, a population-based study in the southeastern United States. Sci Total Environ. 2021;763:144552.","journal-title":"Sci Total Environ"},{"issue":"5","key":"8468_CR18","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1097\/EE9.0000000000000220","volume":"6","author":"EM Lipner","year":"2022","unstructured":"Lipner EM, French JP, Nelson S, Falkinham Iii JO, Mercaldo RA, Blakney RA, et al. Vanadium in groundwater aquifers increases the risk of MAC pulmonary infection in O\u2019ahu, Hawai\u2019i. Environ Epidemiol. 2022;6(5):e220.","journal-title":"Environ Epidemiol"},{"issue":"6","key":"8468_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.201205-0913OC","volume":"186","author":"J Adjemian","year":"2012","unstructured":"Adjemian J, Olivier KN, Seitz AE, Falkinham JO 3rd, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med. 2012;186(6):553\u20138.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08468-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T06:02:27Z","timestamp":1690178547000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08468-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8468"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08468-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"22 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations by the National Institutes of Health\u2019s (NIH) Office of human subjects Research Protection (OHSRP) and the cystic Fibrosis Foundation. The Institutional Review Board (IRB) of the NIH follows all international ethics rules, regulations, and standards. This research protocol was reviewed by NIH OHSRP, which determined that analyses of CFFPR data was \u201cnot human subjects research\u201d, under the 2018 HHS Common Rule (45 CFR 46.102(e)[\n                      \n                      ](ii), 45 CFR 46.116 (b)[\n                      \n                      ](i)), because of the use of deidentified data and, accordingly, exempt from IRB review. For inclusion in the CFFPR, written informed consent was obtained from all subjects and their legal guardian(s) by accredited CF care centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"489"}}